Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease

Author(s): G. Mercuro, M. Deidda, A. Bina, E. Manconi, G. M.C. Rosano.

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 11 , 2011

Become EABM
Become Reviewer

Abstract:

Gender differences in biological substrates of disease determine different clinical manifestations of CV disease with important implications for prevention, diagnosis and therapy in the two sexes. In women, the activity of sex hormones reduces the influence of CV risk factors during the reproductive age, and delays the onset of CHD of 2 decades compared to men. However, women as men suffer from CV events, and in women mortality from all CV causes and have a greater than the sum of the others 7 causes of death together. Women are more likely than men to die of a first myocardial infarction a probability of developing heart failure or a second infarction than their male counterparts. The levels of lipid components vary in different ages of life and in the two genders. TC and LDL increase in men between 35 and 50 years of age. On the contrary LDL levels do not change significantly in fertile women in which they have a lower predictive value for CHD than in men, HDL levels are higher in premenopausal women than in men of the same all age and their role in predicting CHD is considerably higher in women. High triglycerides and Lp(a) are more important as a risk factor in women than in men. Because of the greater incidence of cardiovascular diseases in men until the early 80s, information about the importance of risk factors associated with an increased risk of cardiovascular events has been gathered mainly in men and transferred to women. Most studies on lipid-lowering therapy did not have the adequate statistical power to show significant reductions in CV events in women. Regarding the indications for use of statins in daily practice, current data suggest that in secondary prevention statins are equally effective in both genders while in primary prevention the CV benefits from lipid-lowering therapy in women are less clear than in men and therefore should be used according to the degree of risk calculated from the available score systems.

Keywords: Dyslipidemia, Gender, Primary and secondary prevention, hyperinsulinemia, adolescence, Triglycerides, coagulation, plasminogen, Pharmacotherapy, Gemfibrozil, hyperlipidemia, myalgia, simvastatin, erythromycin, hyperuricemia, Niacin

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 11
Year: 2011
Page: [1082 - 1089]
Pages: 8
DOI: 10.2174/138161211795656954
Price: $58

Article Metrics

PDF: 5